The Enhancer of Zeste Homolog 2 (EZH2) and Embryonic Ectoderm Development (EED) are key components of the Polycomb Repressive Complex 2 (PRC2), which plays a crucial role in epigenetic regulation. The protein-protein interaction (PPI) between EZH2 and EED is essential for the function of the PRC2 complex. This project aims to develop novel PPI inhibitors targeting the EZH2-EED complex, which could potentially lead to new therapeutic strategies for diseases associated with dysregulation of PRC2, such as cancer.

Hepatitis B Virus (HBV) is a significant global health concern, with millions of people affected worldwide. Current therapies primarily target the viral reverse transcriptase and can control the infection indefinitely, but rarely cure patients. The HBV Ribonuclease H (RNAseH) is the second of only two viral enzymes essential for viral replication. It has not been exploited as a drug target, primarily due to the difficulty in producing active enzyme. This project aims to design drugs targeting the HBV RNAseH, which could potentially lead to a cure for HBV.